Insulin Resistance

What is Insulin Resistance?

Insulin resistance is a condition where muscle, fat, and liver cells don’t respond normally to insulin—the hormone that allows cells to take up glucose from the blood. When cells are insulin resistant, the pancreas must produce more insulin to achieve the same effect.

Key concept: Insulin resistance is not just about blood sugar—it’s a metabolic state that increases risk for type 2 diabetes, cardiovascular disease, and other conditions.

How Insulin Resistance Develops

Normal insulin signaling:

Insulin released → Binds cell receptor → Glucose transporters activated → Glucose enters cells

In insulin resistance:

Insulin released → Weak receptor response → Fewer transporters activated → Glucose stays in blood → Pancreas releases more insulin

Causes of Insulin Resistance

Factor	Mechanism
Excess adiposity	Particularly visceral (abdominal) fat
Physical inactivity	Reduced muscle glucose uptake capacity
Genetics	Some populations more susceptible
Inflammation	Chronic low-grade inflammation
Lipotoxicity	Excess fatty acids impair signaling
Aging	Progressive decline in sensitivity

Signs and Consequences

Early signs:

• Acanthosis nigricans (dark skin patches)
• Fatigue after meals
• Difficulty losing weight
• Increased abdominal fat

Metabolic consequences:

Outcome	Mechanism
Hyperinsulinemia	Compensatory insulin production
Prediabetes	Impaired glucose tolerance
Type 2 diabetes	β-cell exhaustion
Dyslipidemia	Abnormal lipid metabolism
Hypertension	Vascular effects
MASH (fatty liver)	Hepatic lipid accumulation

Measuring Insulin Resistance

Test	What It Measures
HOMA-IR	Fasting glucose × fasting insulin / 22.5
Fasting insulin	Baseline insulin levels
OGTT with insulin	Insulin response to glucose
Clamp studies	Gold standard (research only)

Insulin Resistance and Peptides

GLP-1 and dual agonists improve insulin resistance through multiple mechanisms:

Mechanism	Effect on IR
Weight loss	Major improvement (most important)
Direct β-cell effects	Improved insulin secretion
Glucagon suppression	Reduced hepatic glucose output
Delayed gastric emptying	Reduced glucose spikes
Central effects	Improved eating behavior

Clinical trial data:

Medication	HOMA-IR Improvement
Semaglutide	~40-50% reduction
Tirzepatide	~50-60% reduction

Breaking the Cycle

Lifestyle factors:

• Weight loss (5-10% can significantly improve)
• Exercise (especially resistance training)
• Dietary modifications
• Improved sleep

Pharmacological approaches:

• Metformin (first-line)
• GLP-1 agonists (semaglutide, etc.)
• Dual agonists (tirzepatide)
• Thiazolidinediones (insulin sensitizers)

Research Peptides

Some research peptides are being studied for insulin sensitivity:

Peptide	Research Focus
MOTS-c	Mitochondrial peptide, metabolic effects
Humanin	Insulin signaling in preclinical models
Adiponectin mimetics	Insulin sensitization

---

This entry is for educational purposes only. Insulin resistance management should be guided by a healthcare provider.